(VIANEWS) – LGI Homes (LGIH), Saratoga Investment Corp New (SAR), Omega Healthcare Investors (OHI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. LGI Homes (LGIH)
24.3% sales growth and 10.63% return on equity
LGI Homes, Inc. designs, constructs, and sells homes in the United States. It offers entry-level homes, such as detached and attached homes, and move-up homes under the LGI Homes brand name; and luxury series homes under the Terrata Homes brand name. As of December 31, 2020, it owned 113 communities. The company serves in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia, and Pennsylvania. LGI Homes, Inc. was founded in 2003 and is headquartered in The Woodlands, Texas.
Earnings Per Share
As for profitability, LGI Homes has a trailing twelve months EPS of $7.68.
PE Ratio
LGI Homes has a trailing twelve months price to earnings ratio of 17.51. Meaning, the purchaser of the share is investing $17.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.63%.
Volume
Today’s last reported volume for LGI Homes is 94103 which is 58.24% below its average volume of 225385.
Yearly Top and Bottom Value
LGI Homes’s stock is valued at $134.50 at 19:22 EST, under its 52-week high of $141.91 and way above its 52-week low of $84.16.
Earnings Before Interest, Taxes, Depreciation, and Amortization
LGI Homes’s EBITDA is 1.98.
Sales Growth
LGI Homes’s sales growth is 38.6% for the present quarter and 24.3% for the next.
2. Saratoga Investment Corp New (SAR)
12.2% sales growth and 9.41% return on equity
Saratoga Investment Corp. is a business development company specializing in leveraged and management buyouts, acquisition financings, growth financings, recapitalization, debt refinancing, and transitional financing transactions at the lower end of middle market companies. It structures its investments as debt and equity by investing through first and second lien loans, mezzanine debt, co-investments, select high yield bonds, senior secured bonds, unsecured bonds, and preferred and common equity. The firm prefers to invest in aerospace, automotive aftermarket and services, business products and services, consumer products and services, education, environmental services, industrial services, financial services, food and beverage, healthcare products and services, logistics, distribution, manufacturing, restaurants services, food services, software services, technology services, specialty chemical, media and telecommunications. It seeks to invest in the United States. The firm primarily invests $5 million to $50 million in companies having EBITDA of $2 million or greater and revenues of $8 million to $250 million. The firm prefer to take a majority stake. It invests through direct lending as well as participation in loan syndicates. The firm was formerly known as GSC Investment Corp. Saratoga Investment Corp. is based in New York, New York with an additional office in Florham Park, New Jersey.
Earnings Per Share
As for profitability, Saratoga Investment Corp New has a trailing twelve months EPS of $2.74.
PE Ratio
Saratoga Investment Corp New has a trailing twelve months price to earnings ratio of 9.32. Meaning, the purchaser of the share is investing $9.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.41%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 62.5%, now sitting on 128.72M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 102% and a drop 38.3% for the next.
Yearly Top and Bottom Value
Saratoga Investment Corp New’s stock is valued at $25.53 at 19:22 EST, way below its 52-week high of $28.87 and way higher than its 52-week low of $22.63.
3. Omega Healthcare Investors (OHI)
12.1% sales growth and 6.17% return on equity
Omega is a REIT that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the U.S., as well as in the U.K.
Earnings Per Share
As for profitability, Omega Healthcare Investors has a trailing twelve months EPS of $0.98.
PE Ratio
Omega Healthcare Investors has a trailing twelve months price to earnings ratio of 31.35. Meaning, the purchaser of the share is investing $31.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.17%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 855.27M for the twelve trailing months.
Moving Average
Omega Healthcare Investors’s worth is under its 50-day moving average of $32.05 and higher than its 200-day moving average of $30.67.
Volume
Today’s last reported volume for Omega Healthcare Investors is 1380810 which is 32.78% below its average volume of 2054200.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 89.5% and 113.3%, respectively.
4. Regeneron Pharmaceuticals (REGN)
8.6% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.09.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.1. Meaning, the purchaser of the share is investing $24.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 13.1B for the twelve trailing months.
5. WillScot Mobile Mini Holdings Corp. (WSC)
5.9% sales growth and 23.68% return on equity
WillScot Mobile Mini Holdings Corp. provides modular space and portable storage solutions in the United States, Canada, Mexico, and the United Kingdom. The company leases various office space and storage solutions for temporary applications across a customer base in the commercial and industrial, construction, retail, education, health care, government, transportation, security, and energy sectors. . It operates a fleet of over 350,000 portable offices and storage containers. The company is headquartered in Phoenix, Arizona.
Earnings Per Share
As for profitability, WillScot Mobile Mini Holdings Corp. has a trailing twelve months EPS of $1.71.
PE Ratio
WillScot Mobile Mini Holdings Corp. has a trailing twelve months price to earnings ratio of 26.14. Meaning, the purchaser of the share is investing $26.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.68%.
